·		
	Application No.	Applicant(s)
	10/749,537	RABINOWITZ ET AL.
Notice of Allowability	Examiner	Art Unit
	Mina Haghighatian	1616
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>Amendments, Remarks and TDs filed on 09/26/05</u> .		
2. The allowed claim(s) is/are <u>1-3,5,6,11,13 and 15-41</u> .		
3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) ☐ All b) ☐ Some* c) ☐ None of the:		
Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3.  Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
•		
Attachment(s)  1. Notice of References Cited (PTO-892)	5. ☐ Notice of Informal P	atent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Summary Paper No./Mail Dat	(PTO-413),
3. ☑ Information Disclosure Statements (PTO-1449 or PTO/SB/0	<u> </u>	
Paper No./Mail Date <u>09/26/05</u> 4. Examiner's Comment Regarding Requirement for Deposit	8. X Examiner's Stateme	ent of Reasons for Allowance
of Biological Material	9.  Other	

Application/Control Number: 10/749,537

Art Unit: 1616

## Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Barry Swanson on 12/07/05.

The application has been amended as follows:

In the Specification, on page 5, line 4 of section [0030], please add "In certain embodiments the particles have an MMAD of from about 0.2 to about 3 microns.".

In claims 25 and 32, change "0.2" to --0.1--.

In claims 26 and 33 add the term "about" before "0.2" and "3".

## Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The prior art teaches treating insomnia in patients by administering drugs such as zaleplon, zolpidem and zopiclone. The novelty in the instant Application lies within the method of making and administering the <u>condensate</u> aerosols of such drugs. The prior art does not teach producing a condensate by vaporizing the drug particles. Also such condensates provide a degradation product of less than 10% for the particles, an MMAD of less than 5 micron and a peak plasma drug concentration that is reached in less than 0.1 hours.

Application/Control Number: 10/749,537 Page 3

Art Unit: 1616

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mina Haghighatian whose telephone number is 571-272-0615.

The examiner can normally be reached on core office hours.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary L. Kunz can be reached on 571-272-0887. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

PERVISORY PAVENT EXAMINER

Mina Haghighatian

December 07, 2005

Continuation of Substance of Interview including description of the general nature of what was discussed: Examiner telephoned Mr. Swanson to discuss a potential new matter issue with the specification and certain claims. It was suggested to Mr. Swanson to change the particle size range of claims 25 and 32 to read "0.1 to 5" and adding the term "about" before "0.2" and "3" in claims 26 and 33. Specification was suggested to be amended to include the same range also. Mr. Swanson agreed to all the suggestions and it was decided to have the amendments done by an Examiner's amendment (attached).